resTORbio Inc

resTORbio is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of aging-related diseases. The company's initial focus is on the development of RTB101, an orally administered, small molecule, target of rapamycin complex 1 inhibitor, alone and in combination with other mechanistic target of rapamycin inhibitors such as everolimus, as an immunotherapy program designed to improve immune function and thereby reduce the incidence of respiratory tract infections in the elderly regardless of the causative pathogen.
  • TickerTORC
  • ISINUS76133L1035
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

Ashiq Mubarack ...
  • David Nierengarten
  • Robert Driscoll

Q1 Financials; RTB101: PROTECTOR of the Realm?

ValuEngine Rating and Forecast Report for TORC

ValuEngine Rating and Forecast Report for TORC

Ashiq Mubarack ...
  • David Nierengarten
  • Robert Driscoll

Q1 Financials; RTB101: PROTECTOR of the Realm?

ValuEngine Rating and Forecast Report for TORC

ValuEngine Rating and Forecast Report for TORC

ValuEngine Rating and Forecast Report for TORC

ValuEngine Rating and Forecast Report for TORC

ValuEngine Rating and Forecast Report for TORC

ValuEngine Rating and Forecast Report for TORC

ValuEngine Rating and Forecast Report for TORC

ValuEngine Rating and Forecast Report for TORC

ValuEngine Rating and Forecast Report for TORC

ValuEngine Rating and Forecast Report for TORC

ResearchPool Subscriptions

Get the most out of your insights

Get in touch